Zalitin 50 mg/10 ml and 100 mg/20 ml Concentrate for infusion or Solution
PDF Leaflet Revision Date: 15 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic colorectal cancer and adjuvant treatment of stage III colon cancer.
Dosage (summary)
85 mg/mu00b2 IV every 2 weeks for adults.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; may cause irreversible infertility.
Key Drug Interactions
- QT prolonging agents
- Rhabdomyolysis associated drugs
Contraindications
- Hypersensitivity to oxaliplatin
- Breastfeeding
- Bone marrow failure
- Myelosuppression
- Severe renal impairment
Common side effects
- Nausea
- Vomiting
- Neuropathy
- Neutropenia
- Thrombocytopenia
Counselling Points
- Avoid cold exposure during treatment.
- Monitor for signs of infection.
- Report any neurological symptoms immediately.
- Use effective contraception during and after treatment.
Serious warnings
- Serious hypersensitivity reactions
- Neurological toxicity
- Gastrointestinal toxicity
- Cardiac disorders
- Haemolytic-uraemic syndrome
Important Disclaimer
The Zalitin 50 mg/10 ml and 100 mg/20 ml Concentrate for infusion or Solution professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
